Tempus AI (NASDAQ:TEM) Price Target Lowered to $55.00 at Piper Sandler

Tempus AI (NASDAQ:TEM) had its price objective lowered by Piper Sandler from $70.00 to $55.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

A number of other equities research analysts also recently issued reports on TEM. Bank of America increased their price objective on shares of Tempus AI from $54.00 to $60.00 and gave the stock a “neutral” rating in a research note on Monday. Wolfe Research downgraded shares of Tempus AI from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Loop Capital reduced their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. Needham & Company LLC lifted their price target on Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Finally, Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and upped their price objective for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Tempus AI has an average rating of “Moderate Buy” and a consensus target price of $61.18.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $48.86 on Tuesday. The business has a fifty day moving average price of $53.75 and a two-hundred day moving average price of $52.57. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI has a fifty-two week low of $22.89 and a fifty-two week high of $91.45.

Insider Buying and Selling at Tempus AI

In related news, Director Jennifer A. Doudna sold 1,320 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $90.00, for a total value of $118,800.00. Following the sale, the director now owns 36,011 shares of the company’s stock, valued at $3,240,990. The trade was a 3.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Bradley A. Keywell sold 265,000 shares of the firm’s stock in a transaction on Friday, January 17th. The stock was sold at an average price of $35.10, for a total value of $9,301,500.00. Following the transaction, the insider now directly owns 15,218,365 shares of the company’s stock, valued at approximately $534,164,611.50. This represents a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,844,510 shares of company stock worth $321,970,407.

Institutional Trading of Tempus AI

Institutional investors have recently added to or reduced their stakes in the stock. Operose Advisors LLC bought a new position in Tempus AI during the 4th quarter worth approximately $25,000. First Horizon Advisors Inc. acquired a new stake in shares of Tempus AI during the third quarter worth $30,000. Farther Finance Advisors LLC bought a new position in Tempus AI during the fourth quarter worth $34,000. Prestige Wealth Management Group LLC raised its stake in Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after buying an additional 965 shares during the last quarter. Finally, NewEdge Advisors LLC bought a new stake in Tempus AI during the fourth quarter valued at $49,000. 24.22% of the stock is currently owned by institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.